Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05859958 · ClinicalTrials.gov registry record
ABO Blood Group Type Association With COVID-19 Severity
A clinical trial, sponsored by Arrowhead Regional Medical Center.
- Completed
- Registry status
- 599
- Enrollment target
NCT05859958: Completed study, sponsored by Arrowhead Regional Medical Center.
NCT05859958 is a clinical trial that has completed, run by Arrowhead Regional Medical Center. The registered enrollment target is 599 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05859958 has completed, sponsored by Arrowhead Regional Medical Center.
- COMPLETED
- Registry status
- 599 participants
- Enrollment target
Study Summary
The COVID-19 pandemic has caused a significant healthcare burden and remains a heavily researched disease entity. Originating in Wuhan, China in late 2019, SARS-CoV-2 has infected over 600 million individuals worldwide. ABO blood groups have been known to increase the human body's susceptibility to different pathogens, such as hepatitis B virus, MERS-COV, SARS-COV, norovirus, and malaria, to name a few. As such, the association of ABO blood groups and COVID-19 infection and disease severity has come into question.
Primary Outcome
The time spent hospitalized in days.
Interventions
- OTHER No Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 599 participants |
| Start Date | 2022-11-10 |
| Est. Completion | 2023-05-10 |
What the finished NCT05859958 record still lists
NCT05859958 is an observational study that tracks outcomes without assigning an intervention. The registered 599 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which No Intervention is the first listed.
NCT05859958 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05859958 about?
NCT05859958 is a clinical study titled "ABO Blood Group Type Association With COVID-19 Severity". The COVID-19 pandemic has caused a significant healthcare burden and remains a heavily researched disease entity. Originating in Wuhan, China in late 2019, SARS-CoV-2 has infected over 600 million individuals worldwide. ABO blood groups have been known to increase the human body's susceptibility to ...
What is the current status of trial NCT05859958?
This trial is currently completed. The enrollment target is 599 participants. The study started on 2022-11-10. Estimated completion is 2023-05-10.
What interventions are being tested in trial NCT05859958?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT05859958?
This trial is sponsored by Arrowhead Regional Medical Center, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06875973 · 599 participants · Phase 3
Pelacarsen Roll-over Extension Program
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI